XNAS 03 Sep, 2025 4:05 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| James P. Quinlan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.75 per share. | 13 Aug 2025 | 20,000 | 274,147 | - | 2.8 | 55,000 | Common Shares |
| James P. Quinlan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.81 per share. | 13 Aug 2025 | 125,000 | 254,147 | - | 0.8 | 101,250 | Common Shares, no par value ("Common Shares") |
| James P. Quinlan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2025 | 20,000 | 0 | - | - | Stock Option (right to buy) | |
| James P. Quinlan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2025 | 125,000 | 0 | - | - | Stock Option (right to buy) | |
| William L. Ashton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Barry Fishman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Syed Raza Bokhari | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| Edward J. Brennan | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Robert J. Ciaruffoli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Larry Kaiser | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Sara R. May | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Carolyn Bonner | President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| James P. Quinlan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Faisal Mehmud | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Ajay Raju | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 25,000 | 25,000 | - | - | Stock Option (right to buy) |